Breaking News Instant updates and real-time market news.

HALO

Halozyme

$15.93

0.8 (5.29%)

07:23
01/11/19
01/11
07:23
01/11/19
07:23

Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo

Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.

  • 28

    Jan

HALO Halozyme
$15.93

0.8 (5.29%)

10/18/18
PIPR
10/18/18
INITIATION
Target $17
PIPR
Neutral
Halozyme assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Halozyme Therapeutics with a Neutral rating and $17 price target. While the analyst views the Enhanze technology as an "attractive platform that could drive substantial royalty revenue," he has near term concerns around the pivotal HALO-301 study. He believes HALO-301 will need to hit on both progression-free survival and overall survival to support approval and adoption, which tempers his expectations.
11/27/18
CANT
11/27/18
NO CHANGE
Target $27
CANT
Overweight
Halozyme modified Phase 3 design 'a good thing,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating and $27 price target on Halozyme Therapeutics after the company announced that it has made a request to the FDA to change the dual primary endpoints of progression free survival and overall survival of the HALO-301 study to the single primary endpoint of overall survival. On the surface, this "change" can quickly lead to a negative perception of trial progress, Duncan tells investors in a research note titled "Don't Miss the Forest for the Trees - Modified P3 is a Good Thing." However, when assessing the design and rationale, in conjunction with the study remaining blinded, the analyst views the move as "prudent, with the clinical risk thus having been reduced, at least, incrementally." He believes investors appreciate the high-risk in pancreatic cancer, and therefore see low expectations for Phase 3 success being priced into the current share price. Duncan says he has "enhanced non-zero conviction" in the potential for HALO-301 to read out positively in the second half of 2019.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.

TODAY'S FREE FLY STORIES

M

Macy's

$25.13

0.48 (1.95%)

14:42
04/24/19
04/24
14:42
04/24/19
14:42
Periodicals
Macy's in talks to put office tower atop NYC flagship store, Bloomberg reports »

Macy's has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

TCRR

TCR2 Therapeutics

$16.50

-2.2 (-11.76%)

14:40
04/24/19
04/24
14:40
04/24/19
14:40
Conference/Events
TCR2 Therapeutics management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NAII

Natural Alternatives International

$12.52

(0.00%)

14:37
04/24/19
04/24
14:37
04/24/19
14:37
Hot Stocks
Natural Alternatives says beta-alanine for food receives approval in Japan »

The public announcement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$182.74

-1.03 (-0.56%)

14:35
04/24/19
04/24
14:35
04/24/19
14:35
On The Fly
Fly Intel: What to watch in Facebook earnings report »

Facebook (FB) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    May

  • 03

    Jun

WB

Weibo

$69.90

-2.095 (-2.91%)

14:35
04/24/19
04/24
14:35
04/24/19
14:35
Options
Weibo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$138.52

-3.56 (-2.51%)

14:33
04/24/19
04/24
14:33
04/24/19
14:33
Recommendations
Caterpillar analyst commentary at JPMorgan »

Caterpillar pullback a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 12

    Jun

14:25
04/24/19
04/24
14:25
04/24/19
14:25
Conference/Events
SunTrust gov't affairs analysts to hold an analyst/industry conference call »

Analysts hold an…

AMTD

TD Ameritrade

$51.98

-2.3 (-4.24%)

14:23
04/24/19
04/24
14:23
04/24/19
14:23
Recommendations
TD Ameritrade analyst commentary at Deutsche Bank »

TD Ameritrade selloff a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 23

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
04/24/19
04/24
14:17
04/24/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEGN

Aegion

$19.89

0.44 (2.26%)

14:16
04/24/19
04/24
14:16
04/24/19
14:16
Hot Stocks
Aegion names Stephanie Cuskley chair of the board of directors »

Aegion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 02

    May

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
04/24/19
04/24
14:16
04/24/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWL

Newell Brands

$14.06

-0.105 (-0.74%)

14:15
04/24/19
04/24
14:15
04/24/19
14:15
Options
Newell Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

BA

Boeing

$375.35

1.31 (0.35%)

14:15
04/24/19
04/24
14:15
04/24/19
14:15
Periodicals
Garuda to swap 737 MAX orders to other Boeing aircraft, NAR reports »

Gardua Indonesia intends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    Apr

  • 29

    May

  • 05

    Jun

AMZN

Amazon.com

$1,909.19

-14.89 (-0.77%)

14:13
04/24/19
04/24
14:13
04/24/19
14:13
Periodicals
Amazon testing program to combat patent infringement, The Information says »

Amazon is testing a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

NWBI

Northwest Bancshares

$17.43

0.05 (0.29%)

14:07
04/24/19
04/24
14:07
04/24/19
14:07
Hot Stocks
Northwest Bancshares director Robert Campana sells almost $200K in shares »

Northwest Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMC

UMC

$2.00

0.075 (3.90%)

14:03
04/24/19
04/24
14:03
04/24/19
14:03
Upgrade
UMC rating change at HSBC »

UMC upgraded to Hold from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

JNPR

Juniper

$28.67

0.3 (1.06%)

14:00
04/24/19
04/24
14:00
04/24/19
14:00
Options
Active trading in Juniper weeklies ahead of earnings »

Active trading in Juniper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

14:00
04/24/19
04/24
14:00
04/24/19
14:00
General news
Treasury Action: yields remain at or near the lows of the session »

Treasury Action: yields…

SLAB

Silicon Labs

$107.42

13.79 (14.73%)

13:50
04/24/19
04/24
13:50
04/24/19
13:50
Recommendations
Silicon Labs analyst commentary at Roth Capital »

Silicon Labs price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

APC

Anadarko

$71.63

7.51 (11.71%)

, OXY

Occidental Petroleum

$61.03

-1.32 (-2.12%)

13:48
04/24/19
04/24
13:48
04/24/19
13:48
Hot Stocks
Anadarko confirms receipt of unsolicited proposal from Occidental »

Anadarko Petroleum…

APC

Anadarko

$71.63

7.51 (11.71%)

OXY

Occidental Petroleum

$61.03

-1.32 (-2.12%)

CVX

Chevron

$118.75

-3.25 (-2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 30

    Apr

  • 07

    May

  • 10

    May

  • 14

    May

  • 22

    May

  • 29

    May

NYCB

New York Community Bancorp

$11.34

0.02 (0.18%)

13:40
04/24/19
04/24
13:40
04/24/19
13:40
Options
Aggressive call buying in New York Community Bancorp »

Aggressive call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 02

    May

  • 04

    Jun

  • 04

    Jun

  • 11

    Jun

GOOG

Alphabet

$1,259.78

-4.71 (-0.37%)

, GOOGL

Alphabet Class A

$1,266.06

-4.54 (-0.36%)

13:35
04/24/19
04/24
13:35
04/24/19
13:35
Hot Stocks
Google says Google Fit now available on iOS »

Google said in a blog…

GOOG

Alphabet

$1,259.78

-4.71 (-0.37%)

GOOGL

Alphabet Class A

$1,266.06

-4.54 (-0.36%)

AAPL

Apple

$207.60

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 14

    May

  • 03

    Jun

  • 27

    Oct

RIO

Rio Tinto

$59.23

-1.38 (-2.28%)

13:35
04/24/19
04/24
13:35
04/24/19
13:35
Options
Rio Tinto put volume heavy and directionally bearish »

Bearish flow noted in Rio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$24.54

-0.11 (-0.45%)

13:33
04/24/19
04/24
13:33
04/24/19
13:33
Periodicals
Breaking Periodicals news story on Macy's »

Macy's in talks to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

MDSO

Medidata

$89.36

1.74 (1.99%)

, DASTY

Dassault Systemes

$0.00

(0.00%)

13:30
04/24/19
04/24
13:30
04/24/19
13:30
Hot Stocks
Medidata gets second downgrade this week amid reported interest from Dassault »

SunTrust analyst Sandy…

MDSO

Medidata

$89.36

1.74 (1.99%)

DASTY

Dassault Systemes

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    Apr

  • 23

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.